Detalhe da pesquisa
1.
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Bioorg Med Chem Lett
; 26(11): 2631-5, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27106707
2.
Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic.
J Med Chem
; 67(5): 3935-3958, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38365209
3.
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
Antimicrob Agents Chemother
; 56(8): 4161-7, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22615282
4.
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
Bioorg Med Chem Lett
; 22(23): 7201-6, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23021993
5.
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
Bioorg Med Chem Lett
; 22(23): 7207-13, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23084906
6.
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax.
Structure
; 30(7): 947-961.e6, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35460613
7.
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.
ACS Med Chem Lett
; 13(11): 1745-1754, 2022 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36385924
8.
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
Antimicrob Agents Chemother
; 54(1): 305-11, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19841155
9.
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Cell Host Microbe
; 27(4): 642-658.e12, 2020 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32109369
10.
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Bioorg Med Chem Lett
; 19(17): 5132-5, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19648007
11.
Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M4 Positive Allosteric Modulators.
ChemMedChem
; 14(9): 943-951, 2019 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30920765
12.
Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
J Am Chem Soc
; 130(14): 4607-9, 2008 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18338894
13.
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
J Med Chem
; 50(4): 807-19, 2007 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17249648
14.
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.
ACS Med Chem Lett
; 8(12): 1292-1297, 2017 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29259750
15.
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
J Med Chem
; 60(7): 2983-2992, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28245354
16.
Hepatitis C virus NS3/4a protease inhibitors.
Curr Opin Pharmacol
; 30: 84-92, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544488
17.
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.
ACS Med Chem Lett
; 7(7): 702-7, 2016 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27437081
18.
Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2).
Curr Top Med Chem
; 5(9): 869-84, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16178732
19.
In vitro characterization of novel NR2B selective NMDA receptor antagonists.
Neurochem Int
; 46(6): 453-64, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15769547
20.
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.
Pharmacol Res Perspect
; 3(6): e00198, 2015 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27022470